Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies.
Examples of clinical applications of therapeutic hypothermia in modern clinical medicine include traumatic cardiac arrest, ischaemic stroke and, more recently, acute perinatal asphyxia in neonates. The exact mechanism of (neuro)protection by hypothermia is unknown. Since most enzymatic processes exhibit temperature dependency, it can be expected that therapeutic hypothermia may cause alterations in both pharmacokinetic and pharmacodynamic parameters, which could result in an increased risk of drug toxicity or therapy failure. Generalizable knowledge about the effect of therapeutic hypothermia on pharmacokinetics and pharmacodynamics could lead to more appropriate dosing and thereby prediction of clinical effects. This article reviews the evidence on the influence of therapeutic hypothermia on individual pharmacokinetic and pharmacodynamic parameters. A literature search was conducted within the PubMed, Embase and Cochrane databases from January 1965 to September 2008, comparing pharmacokinetic and/or pharmacodynamic parameters in hypothermia and normothermia regarding preclinical (animal) and clinical (human) studies. During hypothermia, pharmacokinetic parameters alter, resulting in drug and metabolite accumulation in the plasma for the majority of drugs. Impaired clearance is the most striking effect. Based on impaired clearance, dosages should be decreased considerably, especially for drugs with a low therapeutic index. Hypothetically, high-clearance compounds are affected more than low-clearance compounds because of the additional effect of impaired hepatic blood flow. The volume of distribution also changes, which may lead to therapy failure when it increases and could lead to toxicity when it decreases. The pH-partitioning hypothesis could contribute to the changes in the volumes of distribution for weak bases and acids, depending on their acid dissociation constants and acid-base status. Pharmacodynamic parameters may also alter, depending on the hypothermic regimen, drug target location, pharmacological mechanism and metabolic pathway of inactivation. The pharmacological response changes when target sensitivity alters. Rewarming patients to normothermia can also result in toxicity or therapy failure. The integrated effect of hypothermia on pharmacokinetic and pharmacodynamic properties of individual drugs is unclear. Therefore, therapeutic drug monitoring is currently considered essential for drugs with a low therapeutic index, drugs with active metabolites, high-clearance compounds and drugs that are inactivated by enzymes at the site of effect. Because most of the studies (74%) included in this review contain preclinical data, clinical pharmacokinetic/pharmacodynamic studies are essential for the development of substantiated dose regimens to avoid toxicity and therapy failure in patients treated with hypothermia.
van den Broek
Marcel P H
MP
Department of Clinical Pharmacy, Division of Laboratory Medicine & Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands. m.p.h.vandenbroek@umcutrecht.nl
Groenendaal
Floris
F
Egberts
Antoine C G
AC
Rademaker
Carin M A
CM
D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007035:Hypothermia / Q000188:drug therapy* / Q000378:metabolism*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism*; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology
D004364:Pharmaceutical Preparations
Crit Care Med. 2009 Jan;37(1):263-9
19050605
Pediatrics. 2008 Apr;121(4):e844-9
18381513
Clin Pharmacokinet. 1987 Mar;12(3):145-67
3555939
J Pharmacol Exp Ther. 1965 Feb;147:260-9
14259505
Arch Pediatr. 2008 Mar;15(3):229-35
18329254
Anesth Analg. 1994 May;78(5):973-7
7909212
Pharmacol Ther. 2008 Oct;120(1):43-53
18718848
J Pharmacol Exp Ther. 1969 Nov;170(1):145-52
5350998
J Pharmacol Exp Ther. 1968 Feb;159(2):389-98
5638659
J Appl Physiol (1985). 2006 Feb;100(2):457-64
16210439
Epilepsia. 2009 Nov;50(11):2355-61
19744111
Anesth Analg. 1995 May;80(5):1007-14
7726398
J Neurosurg. 1993 Sep;79(3):363-8
8360732
J Pediatr. 1982 Apr;100(4):655-60
7062221
Br J Clin Pharmacol. 1991 Dec;32(6):697-704
1768562
Ther Drug Monit. 2001 Jun;23(3):192-7
11360024
Anesthesiology. 2002 Jul;97(1):90-5
12131108
Crit Care Med. 2006 Mar;34(3):785-91
16521272
Acta Anaesthesiol Scand. 1995 Feb;39(2):199-204
7793187
Pediatrics. 2009 Jul;124(1):310-5
19564314
Curr Drug Metab. 2008 Jul;9(6):574-80
18680478
Pharmacology. 1980;20(2):95-100
7384193
J Pharmacol Exp Ther. 1965 Feb;147:252-9
14259504
Mol Pharmacol. 1976 Nov;12(6):977-86
63911
Clin Pharmacokinet. 2006;45(11):1077-97
17048973
J Pharmacol Exp Ther. 1968 Dec;164(2):396-404
5699100
Biochim Biophys Acta. 1990 Oct 8;1031(3):261-75
2223818
Cell Death Differ. 2005 Feb;12(2):162-76
15592434
Am J Physiol. 1978 Aug;235(2):H136-43
28676
Clin Pharmacokinet. 1982 May-Jun;7(3):234-51
7047043
Crit Care Med. 1985 Oct;13(10):844-7
4028756
West J Med. 1983 Feb;138(2):227-32
6837026
Biochem Pharmacol. 1992 Dec 15;44(12):2323-31
1472097
Anesthesiology. 1983 Apr;58(4):357-61
6220624
Anesth Analg. 2005 Apr;100(4):996-1002
15781513
Anesthesiology. 2000 Jan;92(1):84-93
10638903
J Neurochem. 1995 Oct;65(4):1704-11
7561868
Drug Metab Pharmacokinet. 2009;24(1):16-24
19252333
Brain Res. 2007 Jun 11;1153:188-95
17482580
J Clin Pharmacol. 1988 Sep;28(9):860-4
3230153
Am J Physiol. 1953 Apr;173(1):100-2
13050769
Pediatrics. 2009 Jan;123(1):170-2
19117878
Acta Anaesthesiol Scand. 1957;1(1-2):1-13
13487086
Curr Drug Metab. 2008 Mar;9(3):193-8
18336221
Life Sci. 1998;63(26):2365-71
9877226
Can Anaesth Soc J. 1982 Jan;29(1):16-23
7055740
Neonatology. 2008;94(3):203-10
18832856
Anesthesiology. 2001 Feb;94(2):270-9
11176092
Biol Neonate. 2000;77(1):50-7
10658831
Pediatr Neurol. 2005 Jan;32(1):18-24
15607599
BMC Pediatr. 2008 Apr 30;8:17
18447921
Am J Physiol. 1977 Nov;233(5):H605-12
920823
J Pharm Pharmacol. 1986 Feb;38(2):122-5
2870155
J Pharm Pharmacol. 1989 Feb;41(2):125-6
2568421
Clin Sci Mol Med. 1976 Dec;51(6):583-8
1070422
Resuscitation. 2004 Feb;60(2):225-30
15036742
Gen Pharmacol. 1977;8(5-6):305-10
23978
Pharmacol Toxicol. 1990 May;66(5):354-60
2371241
Mol Pharm. 2007 Nov-Dec;4(6):929-35
17927262
Indian Pediatr. 2005 Sep;42(9):928-34
16208054
Indian J Pediatr. 2008 Apr;75(4):385-91
18536895
J Pharm Sci. 1987 Sep;76(9):688-91
11002802
Biochem Biophys Res Commun. 1995 Dec 26;217(3):1193-9
8554576
Anesthesiology. 1978 Nov;49(5):324-9
736287
J Cancer Res Clin Oncol. 1988;114(4):335-40
3410874
Naunyn Schmiedebergs Arch Pharmacol. 1973;280(1):71-8
4273671
J Thorac Cardiovasc Surg. 1965 Mar;49:511-6
14265966
Crit Care Med. 2007 Sep;35(9):2196-204
17855837
J Physiol. 1970 Feb;206(2):38P-39P
5498490
Curr Neurol Neurosci Rep. 2008 Nov;8(6):508-17
18957189
J Thorac Cardiovasc Surg. 2004 May;127(5):1270-5
15115982
Anesth Analg. 2002 May;94(5):1298-303, table of contents
11973207
Neuropharmacology. 2008 Sep;55(3):363-89
18308347
Biol Pharm Bull. 2007 Sep;30(9):1763-7
17827736
Anesth Analg. 2001 Jul;93(1):234-8
11429373
Anesthesiology. 1991 May;74(5):815-9
1673591
Cancer Chemother Pharmacol. 1997;40(5):419-24
9272119
Ann Thorac Surg. 1992 Jun;53(6):957-64
1596156
Anesth Analg. 1990 Aug;71(2):158-70
2375517
Resuscitation. 1974;3(4):265-71
4467280
J Clin Pharmacol. 2008 Oct;48(10):1226-36
18559487
J Matern Fetal Neonatal Med. 2007 May;20(5):407-10
17674246
J Pharmacol Exp Ther. 1978 Nov;207(2):532-8
712635
Chest. 2008 May;133(5):1267-74
18460529
Pharm Res. 1987 Jun;4(3):248-50
3509290
Br J Anaesth. 2000 Apr;84(4):443-9
10823093
Neonatology. 2009;96(4):211-8
19407466
Br J Anaesth. 1987 Nov;59(11):1459-64
2825743
Perfusion. 2004 Jan;19(1):53-63
15072256
J Hepatol. 1987 Apr;4(2):259-68
3295021